Cargando…
Adenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: case report
The treatment of lung cancer has made paradigm-shift advancements in the past decade with the development of therapies directed at specific genetic alterations, such as epidermal growth factor receptor (EGFR). Here, we present a rare case of lung adenocarcinoma harboring EGFR activating mutation and...
Autores principales: | Xu, Li, Wang, Qian Z, Wu, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602471/ https://www.ncbi.nlm.nih.gov/pubmed/28979143 http://dx.doi.org/10.2147/OTT.S143501 |
Ejemplares similares
-
Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
por: Sun, Ruizhu, et al.
Publicado: (2022) -
Lung adenocarcinoma with EGFR gene mutation metastatic to the uterine cervix: A case report
por: Wang, Yong, et al.
Publicado: (2020) -
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018) -
Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021) -
Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)